Results 1 to 10 of about 10,552 (197)

The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta

Scientific Reports, 2021
The aim of this study was to present and evaluate novel oral vaccines, based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum, to neutralize severe acute
Reza Keikha, Ali Jebali, Seyed Mohammad Hashemi-Shahri   +2 more
exaly   +3 more sources

Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo [PDF]

Nature Communications
Self-amplifying mRNA (saRNA) vectors hold promise for the sustained expression of mRNA vaccines in vivo. However, their inherently high immunogenicity and low-fidelity replication—stemming from the RNA viral genome’s replication mechanisms—limit their ...
Zunyong Feng, Liuxi Chu, Qiang Li, Jing Zhou, Ping Wu, Xuanbo Zhang, Yuanbo Pan, Jianhua Zou, Qun Chen, Zhiliang Xu, Liang Yan, Yanjiao Huang, Xiaokun Li, Zhouguang Wang, Xiaoyuan Chen   +14 more
doaj   +3 more sources

Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

Vaccines, 2023
Although conventional vaccine approaches have proven to be successful in preventing infectious diseases in past decades, for vaccine development against emerging/re-emerging viruses, one of the main challenges is rapid response in terms of design and ...
Qinxue Hu, Yalan Liu, Liu Yalan
exaly   +2 more sources

Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach

Molecular Pharmaceutics, 2022
Lipid nanoparticles (LNPs) are the leading technology for RNA delivery, given the success of the Pfizer/BioNTech and Moderna COVID-19 mRNA (mRNA) vaccines, and small interfering RNA (siRNA) therapies (patisiran).
Anna Blakney, Zoltan Kis
exaly   +2 more sources

Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: Progress, evidence gaps, and translational pathways for durable and scalable immunization. [PDF]

Hum Vaccin Immunother
Self-amplifying RNA (saRNA) and circular RNA (circRNA) are emerging vaccine modalities that extend conventional, non-replicating mRNA platforms. Self-amplifying RNA encodes a replicase that amplifies intracellular RNA templates, enabling high antigen ...
Okechukwu Paul-Chima U, Michael Ben O, Fabian C O, Jovita Nnenna U, Chinyere N U.   +4 more
europepmc   +2 more sources

Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and saRNA future therapies

Frontiers in Cell and Developmental Biology, 2023
Neurodevelopmental disorders encompass a group of debilitating diseases presenting with motor and cognitive dysfunction, with variable age of onset and disease severity.
Serena Barral, Manju A Kurian Or Ma Kurian, Kilpinen Helena   +2 more
exaly   +2 more sources

Systemic MyoAAV-saRNA delivery activates endogenous utrophin and rescues dystrophic pathology in mdx mice. [PDF]

Regen Ther
Background Therapeutic activation of endogenous utrophin, a homolog of dystrophin, represents a mutation-agnostic therapeutic strategy with considerable potential for treating Duchenne muscular dystrophy (DMD).
Xiahou Z, Wang T, Zhang Z, Li N, Xiao H, Li Z, Gan Y, Hou X, Song Y.   +8 more
europepmc   +2 more sources

Influence of the administration route and dose on the expression and antibody responses of a reporter and avian influenza self-amplifying mRNA vaccine in poultry [PDF]

Veterinary Quarterly
Vaccination is routinely used in industrial poultry to control infectious diseases. Vaccines based on mRNA and self-amplifying RNA (saRNA) are approved for human use, but research on their application in poultry is limited.
Janne Snoeck, Xiaole Cui, Pieter Vervaeke, Niek N. Sanders, An Garmyn   +4 more
doaj   +2 more sources

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration

Molecular Therapy - Nucleic Acids, 2023
A large proportion of patients with chronic myeloid leukemia (CML; 20%–50%) develop resistance to imatinib in a BCR-ABL1-independent manner. Therefore, new therapeutic strategies for use in this subset of imatinib-resistant CML patients are urgently ...
Jia Fei, Xiuyuan Wang, Juhua Yang
exaly   +2 more sources

A Mutation in Endogenous saRNA miR-23a Influences Granulosa Cells Response to Oxidative Stress

Antioxidants, 2022
Phenotypes are the result of the interaction between the gene and the environment, so the response of individuals with different genotypes to an environment is variable.
Xing Du, Qifa Li, Siqi Wang
exaly   +2 more sources